Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Pediatrics Cost Effectiveness Cardiology

CobiCure Will Develop Cardiac Devices For Children, Sans Profit Motive

  • Interviews

Executive Summary

CobiCure is pursuing a non-profit approach to the development of cardiac devices for underserved patient populations.

You may also be interested in...



Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future

Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.

Investor Eye: Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future

Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.

Minute Insight: Cordis-MedAlliance Deal Formalized, Less Than One Year After Announcement

The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.

Table

View full table

Topics

Tags:
Pediatrics Cost Effectiveness Cardiology
Latest Headlines

Why Investing In ESG Measures Is Good For Medtech’s Health And Sustainability

IVD DNA Test For Cancer Receives New Regulatory Classification

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

Stakeholders Give FDA An Earful; Poor Communication, Recall Inefficiency, Patients At Risk

See All
UsernamePublicRestriction

Register

MT145658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By